Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran

J Pharmacol Exp Ther. 2016 Feb;356(2):305-13. doi: 10.1124/jpet.115.229823. Epub 2015 Nov 17.

Abstract

The antithrombin activity of unfractionated heparin (UFH) is offset by extracellular histones, which, along with DNA, represent a novel mediator of thrombosis and a structural component of thrombi. Here, we systematically evaluated the effect of histones, DNA, and histone-DNA complexes on the anticoagulant and profibrinolytic activities of UFH, its derivatives enoxaparin and fondaparinux, and the direct thrombin inhibitor dabigatran. Thrombin generation was assessed by calibrated automated thrombinography, inhibition of factor Xa and thrombin by synthetic substrates, tissue plasminogen activator-mediated clot lysis by turbidimetry, and thrombin-activatable fibrinolysis inhibitor (TAFI) activation by a functional assay. Histones alone delayed coagulation and slightly stimulated fibrinolysis. The anticoagulant activity of UFH and enoxaparin was markedly inhibited by histones, whereas that of fondaparinux was enhanced. Histones neutralized both the anti-Xa and anti-IIa activities of UFH and preferentially blocked the anti-IIa activity of enoxaparin. The anti-Xa activity of fondaparinux was not influenced by histones when analyzed by chromogenic substrates, but was potentiated in a plasma prothrombinase assay. Histones inhibited the profibrinolytic activity of UFH and enoxaparin and enhanced that of fondaparinux by acting on the modulation of TAFI activation by anticoagulants. Histone H1 was mainly responsible for these effects. Histone-DNA complexes, as well as intact neutrophil extracellular traps, impaired the activities of UFH, enoxaparin, and fondaparinux. Dabigatran was not noticeably affected by histones and/or DNA, whatever the assay performed. In conclusion, histones and DNA present in the forming clot may variably influence the antithrombotic activities of anticoagulants, suggesting a potential therapeutic advantage of dabigatran and fondaparinux over heparins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticoagulants / metabolism*
  • Anticoagulants / pharmacology
  • Bothrops
  • Cattle
  • Dabigatran / metabolism*
  • Dabigatran / pharmacology
  • Dose-Response Relationship, Drug
  • Factor Xa / metabolism
  • Female
  • Fibrinolytic Agents / metabolism*
  • Fibrinolytic Agents / pharmacology
  • Heparin / metabolism*
  • Heparin / pharmacology
  • Histones / metabolism*
  • Histones / pharmacology
  • Humans
  • Male
  • Thrombin / antagonists & inhibitors
  • Thrombin / metabolism

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Histones
  • Heparin
  • Thrombin
  • Factor Xa
  • Dabigatran